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Abstract
Introduction. Integrated care, by allowing information exchange among health profes-
sionals, improves outcomes and favours a reduction in hospital admission in diabetes. 
Retinal complications can be sight-threatening, and diabetic patients often miss the sug-
gested yearly clinical examination. 
Methods. Teleretinography can be easily performed in patients attending Diabetes Clin-
ics: images are sent to a remote ophthalmologist, grading and instructions are received 
and forwarded to General Practitioners by a dedicated software. 
Results. We here report the results of teleretinography performed in our Diabetes Clinic 
in 362 patients missing the yearly fundus examination: 253 patients showed no diabetic 
retinopathy, 86 a mild form, and 23 needed referral to hospital settings. 
Conclusions. Teleretinography is a user-friendly, time-saving and cost-effective tech-
nique, easily integrable into integrated care, allowing a better adherence to guidelines. 
INTRODUCTION
Population and financial factors drive public health’s 
efforts toward a cost-effective “integrated care” (IC) 
model of chronic disease management; interaction be-
tween primary and secondary care structures prevents 
providing the patient with fragmented (if not conflict-
ing) inputs from different health professionals, and de-
creases demand for hospital admissions [1, 2]. In dia-
betes, several studies have shown that IC is associated 
with an improvement in metabolic control indicators 
(HbA1C, blood pressure, serum lipids, body mass in-
dex) and a reduction in hospital admission [1, 3-5]. In 
Italy, the diabetes IC programme (IGEA, Integration, 
Management and Assistance to the Diabetic patient) 
started in 2009 [6].
Teleretinography (digital imaging of the ocular fun-
dus) is a simple, cost-effective and rapidly spreading 
technique [7-10], and relevant international scientific so-
cieties recommend its use for diabetic retinopathy (DR) 
screening [11, 12], with several reports [13-17] showing 
its clinical- and cost-effectiveness. In the UK, all eligible 
diabetic patients are annually telescreened in the NHS 
Diabetic Eye Screening Programme (DESP) [18].
A national survey in Italy [19] showed that no more 
than 20% of diabetic patients undergo a yearly fundus 
examination, thus jeopardizing early identification of 
incipient DR.
Patients routinely attending our Diabetes Clinic (DC) 
in Pescara, Italy, have their fundus photographed with a 
digital fundus camera. Images are sent to a remote oph-
thalmologist (“store-and-forward” method), and grad-
ing and follow-up recommendations are forwarded to 
the General Practitioners (GPs). Cases needing referral 
are rapidly sent to the ophthalmology service.
Patients enrolled in IC have their clinical fundus ex-
amination replaced with teleretinography. We report 
the results of a 10-month experience of digital fundus 
imaging in patients who had missed routine controls in 
ophthalmic settings.
 
MATERIALS AND METHODS
An asp.net technology-based software was imple-
mented (QUICKConnect, opeNETica, Montesilvano, 
Pescara, Italy), allowing a complete data exchange 
among the different data archiving softwares used by 
the GPs. GPs attended courses to manage the software 
and to share common guidelines on diabetes treatment, 
and were asked to send patients to the DC for fundus 
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examination, an alternative to retinal examination in an 
ophthalmic setting. 
From January to October, 2014, 362 diabetic pa-
tients: 207 males (57.18%) and 155 females (42.82%); 
ages 21-82, median 63; 9 type I (2.48%) and 353 type II 
(97.52%), at their first admission in our DC and miss-
ing the yearly fundus examination, underwent retinog-
raphy with a digital fundus camera (DRS, CenterVue, 
Fremont, CA, USA). All patients were dilated with 
Tropicamide 1% (Visumidriatic 1%, Visupharma, Italy). 
Median time from drop administration to exam was 
20 minutes (10-35). Time for personal data recording 
and image taking, operated by non-medical personnel, 
ranged from 5 to 10 minutes. No additional cost be-
yond those of the instrument and drops was required. 
A set of two 40x45 images was taken in each eye, one 
centered at the optic disc and the other at the fovea. 
On a “store-and-forward” basis, the records were sent 
to an ophthalmologist trained in DR, who examined 
both a color and a digitally filtered red-free image for 
every field, and graded diabetic retinopathy accordingly 
with the NHS-DESP classification (Table 1) [20, 21]. 
Grading and suggested follow-up were sent back to the 
DC in a week’s time, downloaded by diabetologists into 
the patients’ electronic records, and forwarded to GPs. 
Admission to hospital ophthalmic settings was immedi-
ately planned for cases needing referral.
The procedure was routinely performed with the pa-
tients’ informed consent (both for pupil dilation and for 
image management), and data collected in compliance 
with the tenets of the Declaration of Helsinki. The pres-
ent note is a report of routine clinical practice, and is 
not intended as an observational study.
RESULTS
The involvement of GPs in the IGEA project has 
been rapidly growing, with 156 out of 196 doctors 
(79.6%) participating since the beginning of the proj-
ect in January 2014, becoming 176 out of 196 (89.8%) 
at October 2014. The amount of diabetes-related re-
cords exchanged (GPs to diabetologists and viceversa) 
grew from 349 in January to 1264 in October. After ten 
months, 89.8% of GPs had a total 73% of their diabetic 
patients enrolled in IC. Patient data (Figure 1) showed 
an increase in: number of HbA1C measurements; 
HbA1C values < 7.5% (< 58 mmol/mol); LDL-choles-
terol < 130 mg/dl (< 3.3 mmol/L); blood pressure (BP) 
< 130/80 mmHg; number of creatinin measurements. 
A slightly lower result appeared in the number of body 
mass index and BP measurements, what immediately 
led to correct clinical routine. 
All retinal images were clear enough to be graded. 
Among the 362 patients (Table 2), 253 R0M0 (69.89%) 
and 86 R1M0 (23.75%) were invited to repeat reti-
nography in a year’s time; 10 R1M1 (2.76%), 8 R2M0 
(2.21%) and 4 R2M1 (1.10%) were referred to oph-
thalmology within two weeks; one R3M1 (0.25%) with 
preretinal hemorrhage was immediately referred to 
ophthalmology for treatment. Comorbidities were iden-
tified, some of which needing referral to the hospital 
setting for further diagnosis and therapy: 151 patients 
with various stages of Age-Related Macular Degenera-
tion (ARMD, ranging from isolated drusen to atrophy 
and neovascularization, 41.71%); 54 with hypertensive 
retinopathy (Keith-Wagener-Barker’s stage II or more, 
14.91%); 18 with suspect glaucomatous cupping of the 
optic disc (4.97%); 8 with vitreoretinal interface shrink-
ing (2.20%).
DISCUSSION
A meta-analysis of 53 controlled trials [1] showed a 
statistically significant reduction (up to 19%) in the risk 
of hospitalization for diabetic patients enrolled in IC 
programs. A German experience in the region of Sax-
ony [3], involving 75% of GPs, 100% of diabetologists 
and about 90% of the diabetic population, was aimed 
at HbA1c and blood pressure control. A narrowing of 
the regional differences in therapeutic management 
and outcome and an approximation to targets as de-
fined by the guidelines were obtained. The authors 
highlighted the importance of both the timely referral 
of patients to the diabetologist by the GP and the im-
proved competence in the disease treatment by the GP, 
trained in quality workshops provided by diabetologists, 
and stated that collective disease management data ex-
change and discussion was crucial for the success of 
the program, helping breaking down barriers between 
the two care levels. A Saudi-Arabian experience [4] led 
the Authors to state that “dynamic tailoring of the care 
components in response to patient’s need may have 
contributed to improved glycemic control”. In Ireland, 
a guideline on IC was produced [5] involving patients, 
GPs, practice nurses, diabetologists, clinical nurses 
specialist in diabetes, dieticians, ophthalmologists and 
podiatrists, with a facilitated access to endocrinology, 
vascular, cardiology, nephrology and psychology servic-
Table 1
Diabetic retinopathy lesions classification
Level R0 – None
Level R1 – Background
• Microaneurysm(s)
• Retinal haemorrhage(s) ± any exudate
Level R2 – Pre-proliferative
• Venous beading
• Venous loop or reduplication
• Intraretinal microvascular abnormality (IRMA)
• Multiple deep, round or blot haemorrhages
• Cotton wool spots (CWS – careful search for above features)
Level R3 – Proliferative
• New vessels on disc (NVD)
• New vessels elsewhere (NVE)
• Pre-retinal or vitreous haemorrhage
• Pre-retinal fibrosis ± tractional retinal detachment
Maculopathy (M0 – nil present, M1 – maculopathy)
• Exudate within 1 disc diameter (DD) of the center of the fovea
• Circinate or group of exudates within the macula
•  Retinal thickening within 1DD of the centre of the fovea  
(if stereo available)
•  Any microaneurysm or haemorrhage within 1DD of the centre 
of the fovea only if associated with a best visual acuity of ≤ 6/12 
(if no stereo)
Photocoagulation (P)
• Focal/grid to macula
• Peripheral scatter
Unclassifiable (U)
• Ungradable/unobtainable
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es as needed, stressing the fundamental importance of 
the “register-review-recall” paradigm.
A 2004 report [22] highlighted the fundamental im-
portance of involving primary care clinicians in prevent-
ing vision loss from chronic eye disease.
In Italy, the IGEA project [6, 23], managed by the 
Ministry of Health and the Istituto Superiore di Sanità, 
was implemented in 2009 to improve the quality of care 
by: guaranteeing effective intervention for all persons 
with diabetes, measuring both processes and outcomes; 
promoting multi-disciplinary care teams involving pri-
mary and secondary care levels; aiming at the diffusion 
of the model to the entire Country accordingly with lo-
cal organizations. 
Implementation of IGEA in our DC involving diabe-
tologists, GPs and an ophthalmologist started in Janu-
ary, 2014. 
The ACCORD study [24] showed that DR is related 
to cardiovascular events, thus acting as a marker of sys-
temic disease. Allowing an in vivo visualization of small 
vessels, the retina is also a marker of microangiopathy, 
which is linked to serum lipids [25], blood pressure [26] 
and microalbuminuria [27]. Within the retina, a correla-
tion has been shown [28] between microaneurysm turn-
over and development of clinically significant macular 
oedema, one of the main causes of blindness worldwide. 
The strong value of retinography in identifying both 
ocular and systemic diseases is well known [29, 30].
In our DC, teleretinography has become part of IC, 
and images, grading and suggested follow-up are avail-
able online to both diabetologists and GPs in a few 
days. Our results confirm that poorly compliant pa-
tients can show referable stages of retinal microangi-
opathy and/or comorbidities. Teleretinography helped 
starting a proper care pathway and informing patients 
about the serious consequences of missing periodical 
examinations.
CONCLUSIONS
We consider retinal microangiopathy a clinical out-
come in IC. Performing teleretinography in the DC 
overcomes the problem of limited access of patients 
to clinical fundus examination [19, 31, 32], allowing a 
better EBM-based follow-up of patients. The camera is 
operated by non-medical personnel, ophthalmologists’ 
worktime for fundus examination (in Italy, scheduled 
DM03    At least 1 HbA1C record
DM04    HbA1C < 7.5 % (< 58 mmol/mol) YELLOW = GUIDELINES' STANDARD PERFORMANCE
DM05    At least 1 C-LDL record
DM06    C-LDL < 130 mg/dl (< 3.3 mmol/L) RED = PATIENTS’ PERFORMANCE
DM07    At least 1 BP record
DM08    BP < 130/80 mmHg 
DM09    At least 1 BMI record
DM10    At least 1 waist circumference record
DM11    At least 1 microalbuminuria record
DM12    At least 1 creatinin record
DM08
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DM09 DM07
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DM06
DM05
DM10
DM11
70%
90%
80%
100%
70%
80%
90%
Figure 1
Patients’ performance: not in integrated care (left) – in integrated care (right).
Table 2
Distribution of pathologies
Pathology Patients Percentage
Diabetic retinopathy, stage
• R0M0 253 69.89
• R1M0 86 23.75
• R2M0 8 2.21
• R1M1 10 2.76
• R2M1 4 1.10
• R3M1 1 0.25
Age-related macular degeneration 151 41.71
Hypertensive retinopathy* 54 14.91
Glaucoma suspect 18 4.97
Vitreoretinal interface syndrome 8 2.20
*Keith, Wegener, Barker stage II or more.
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outpatient time is 15-20 minutes) is reduced, and im-
ages can be graded out of clinical routine. 
Portable fundus cameras [33], with images conveyed 
to reading centres, can help extend the screening activ-
ity to the entire network of GP practices, to assure a 
standardized and capillary diffusion of early detection 
of retinal microangiopathy. We believe that the slight 
GPs’ overwork in dilating the patients’ pupils is worth 
the result of an increased diabetic population coverage.
Our ongoing experience in DR telecreening is aimed 
at paralleling the UK effort in covering the entire dia-
betic population, by taking fundus photographs in every 
patient attending the DCs and the GP practices, and 
calling the unattending ones. 
In 2003 UK produced a complete HTA report on 
digital imaging in DR [34]; recently, it established a pro-
tocol [35] to define an HTA on the attendance to DR 
controls, reporting as an early indicator of the success 
of the NHS Diabetic Eye Screening Programme [18] 
the drop in the numbers of blindness certifications at-
tributable to diabetic retinopathy in England and Wales 
in working age adults (16-64 years), from 17.7% in 1999 
to 2000 to 14% in 2009-2010. In Italy, the incidence of 
blindness from diabetes is 2-3 cases/100 000/year under 
age 70, and 6-12 cases/100 000/year over age 70 [36]. 
Blindness from DR is avoidable in most cases, and the 
UK experience shows the effectiveness of early identifi-
cation and treatment [37], thus fulfilling both the 1968 
Wilson and Jungner’s [38] and the 2008 World Health 
Organization’s [39] criteria for screenings.
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